| |
Unselected post-infarction patients
|
Post-infarction patients with left ventricular dysfunction
|
|---|
|
Trial
|
CONSENSUS II
|
GISSI-3
|
ISIS-4
|
SAVE
|
AIRE
|
SMILE
|
TRACE
|
|---|
|
[Reference no]
|
[16]
|
[8]
|
[7]
|
[10]
|
[12]
|
[9]
|
[11]
|
|---|
|
Drug
|
Enalapril
|
Lisinopril
|
Captopril
|
Captopril
|
Ramipril
|
Zofenopril
|
Trandolapril
|
|
Number of patients
|
6090
|
19,394
|
58,050
|
2231
|
2006
|
1556
|
1749
|
|
Target dose
|
20 mg × 1
|
10 mg × 1
|
50 mg × 2
|
50 mg × 3
|
5 mg × 2
|
30 mg × 2
|
4 mg × 1
|
|
Inclusion criteria
|
AMI
|
AMI
|
AMI
|
LVEF < 40%
|
Signs or
|
Anterior wall
|
Low wall
|
| |
consecutively
|
consecutively
|
consecutively
| |
symptoms of
|
AMI without
|
motion index
|
| | | | | |
heart failure
|
thrombolytics
|
score
|
|
Follow-up time
|
1.5-6 months
|
6 weeks
|
5 weeks
|
24-60 months
|
6-30 months
|
6 weeks
|
24-50 months
|
| |
(trial stopped)
| | | | | | |
|
Mortality reduction
|
P: 10.2%
|
P: 7.1%
|
P: 7.7%
|
P: 25%
|
P: 23%
|
P: 10.6%
|
P : 42.3%
|
| |
T: 11.0%
|
T: 6.3%
|
T: 7.2%
|
T: 20%
|
T: 17%
|
T: 7.1%
|
T: 34.7%
|
|
Risk reduction
|
-10 %
|
12%
|
7%
|
19%
|
27%
|
25%
|
22%
|
|
(95% CI)
|
(-29 to 7%)
|
(1% to 21%)
|
(1% to 13%)
|
(3% to 32%)
|
(11% to 40%)
|
(-11% to 60%
|
(9% to 33%)
|
|
Level of significance
|
P = 0.26
|
P = 0.03
|
P = 0.02
|
P = 0.019
|
P = 0.002
|
P = 0.19
|
P = 0.001
|
- AMI, acute myocardial infarction; LVEF, left ventricular ejection fraction; P, placebo; T, treatment; CI, confidence interval.
